Isolated testicular vasculitis due to immune checkpoint inhibitor

Rebecca Weiner¹, Britt Hanson², Jamaal Rehman³, Bob Sun⁴

Abstract

Immune checkpoint inhibitors are increasingly being used to treat various malignancies; consequently, more rheumatological side effects, ranging from arthritis to vasculitis, are being reported. Here we present, for the first time, a case of vasculitis involving the testicle in the setting of an immune checkpoint inhibitor. As reported in previous cases, recurrence of a malignancy, as opposed to vasculitis, was initially suspected, thus creating a diagnostic dilemma. These rheumatological side effects have garnered attention as they potentially provide a window into the pathogenesis of rheumatological diseases.

Keywords: Vasculitis, immune checkpoint inhibitors, malignancy

Introduction

To combat malignancy, immune checkpoint inhibitors are used to augment antitumor activity by enhancing unopposed T-cell activity (1). However, exploiting this aspect of the immune system has led to a variety of inflammatory side effects deemed immune-related adverse events (IRAEs) (2). Rheumatologists should be aware of these complications, as there are increasing reports of rheumatological sequelae such as arthritis, myositis, and sicca syndrome (3). Vasculitis is a less commonly reported rheumatologic IRAE, and we present, to our knowledge, the first case report of isolated testicular vasculitis induced by the checkpoint inhibitor ipilimumab, an antagonist of cytotoxic T lymphocyte-associated protein 4 (CTLA-4).

Case Presentation

A 61-year-old man with no history of any autoimmune disease was diagnosed with stage IIIB malignant melanoma. He was treated with wide excision of the cancer followed by adjuvant ipilimumab (10 mg/kg) therapy. One week after the second ipilimumab dose, he developed a rash consistent with a cutaneous IRAE, which was treated with a short course of methylprednisolone. Then, 1 week later, he developed acute abdominal discomfort with fever (body temperature, 39.4°C) and leukocytosis (leukocyte count, 16,200/µL), prompting an initial concern for checkpoint inhibitor-mediated colitis. Imaging studies were consistent with diverticulitis, and antibiotics were initiated. Two days after developing abdominal pain, he developed bilateral testicular pain. Bilateral epididymal and testicular tenderness, induration, and enlargement (left greater than right) was noted; pelvic magnetic resonance imaging revealed solid bilateral testicular masses. Concern for malignant metastasis to the testes prompted a left groin exploration and orchiectomy. Intraoperatively, the testicle was grossly necrotic in appearance, concerning for bilateral necrotizing orchitis. Pathological examination revealed medium-vessel vasculitis of the left testicle and no malignancy (Figure 1).

The antinuclear antibody, antineutrophil cytoplasmic antibody, and hepatitis B and C serology results were negative, and urinalysis findings were normal. C-reactive protein (CRP) levels were elevated (149 mg/L; normal range, <4.9 mg/L). Given the lack of evidence for systemic vasculitis, the patient was diagnosed with isolated testicular vasculitis. Ipilimumab was discontinued, and 100 mg (1 mg/kg) of prednisone was initiated and tapered over 6 weeks. There was no recurrence of testicular vasculitis or development of a systemic vasculitis. CRP levels normalized, and no additional immunosuppression was needed.

Literature Review

Vasculitis is one of the less commonly reported rheumatologic IRAEs (4). Interestingly, while systemic vasculitis diseases, such as giant cell arteritis, have been reported, there have been reports of single-organ vasculitis (5). For example, in addition to our report of the isolated testicular vasculitis, vasculitis involving the retina (6), uterus (7), and brain (8) has been reported. Treatment for most cases included checkpoint

Acknowledgments

We sincerely appreciate the contributions of our colleagues in Internal Medicine, Hematology, Pathology, and Rheumatology at NorthShore University HealthSystem. The authors declare no conflicts of interest.

References

1. Banchereau J, Cohen J, Jonuleit H, et al. (2019) The role of immune checkpoint inhibitors in cancer therapy. Nat Rev Immunol 19: 129–144.
2. Topalian SL, Kaukinen T, Yang JC, et al. (2019) Checkpoint inhibition in the treatment of cancer: mechanisms, strategies, and clinical outcomes. JAMA Oncol 5: 119–129.
3. McManus CR, Jaffe ES, Weksler BB, et al. (2019) Cancer immunotherapy: a new era of shared success. J Clin Oncol 37: 1221–1226.
4. Bronte V, Curiel DL, Hafler DA, et al. (2019) The role of immune checkpoint inhibitors in the treatment of cancer: mechanisms, strategies, and clinical outcomes. JAMA Oncol 5: 119–129.
5. Arora S, Doherty M, Arora S, et al. (2019) The role of immune checkpoint inhibitors in the treatment of cancer: mechanisms, strategies, and clinical outcomes. JAMA Oncol 5: 119–129.
6. Bouchet J, Bouchet J, Bouchet J, et al. (2019) The role of immune checkpoint inhibitors in the treatment of cancer: mechanisms, strategies, and clinical outcomes. JAMA Oncol 5: 119–129.
7. de la Cámara P, de la Cámara P, de la Cámara P, et al. (2019) The role of immune checkpoint inhibitors in the treatment of cancer: mechanisms, strategies, and clinical outcomes. JAMA Oncol 5: 119–129.
8. Fehrenbacher L, Fehrenbacher L, Fehrenbacher L, et al. (2019) The role of immune checkpoint inhibitors in the treatment of cancer: mechanisms, strategies, and clinical outcomes. JAMA Oncol 5: 119–129.
inhibitor cessation and high-dose corticosteroids, which resulted in a rapid clinical improvement. No recurrences were noted in any cases, and additional immunosuppression was not required. It is imperative to distinguish an IRAE from a malignant metastasis in patients receiving immune checkpoint inhibitors. In the present case, as well as the other three isolated organ vasculitis cases, the initial concern was metastatic spread, rather than the actual diagnosis: autoimmune vasculitis induced by an immune checkpoint inhibitor.

As the use of immune checkpoint inhibitors continues to grow, we suspect that more cases of vasculitis induced by these medications will be reported, which will help further elucidate the trends. By understanding the mechanism of rheumatologic IRAEs induced by checkpoint inhibitors, hopefully more insight can be gained into the pathogenesis of rheumatological diseases. Ongoing research seeks to determine whether there are predispositions to vasculitis based on depleted levels of costimulatory molecules (9). These studies demonstrate low levels of programmed death-ligand 1 (PD-L1) in temporal artery biopsies of patients with giant cell arteritis (10). This finding, which mimics the fundamental principle of a checkpoint inhibitor, may shed light on the mechanism of vasculitis induced by checkpoint inhibitors (11). PD-L1 and CTLA-4 levels have been shown to be integral in the development of inflammatory conditions. Further research may help determine whether it is possible to manipulate the levels of these immune checkpoint inhibitors to prevent autoimmune potentiation.

**Conclusion**

The relationship between immune checkpoint inhibitors and rheumatological conditions continues to evolve. When using immune checkpoint inhibitors, one must be aware that there is a possibility of occurrence of vasculitis, as opposed to recurrence of a malignancy. The increasing reports of vasculitis occurring in the setting of immune checkpoint inhibitors will lead to a better understanding of the pathogenesis of vasculitis.

**Main Points**

- Vasculitis can be a complication of immune checkpoint inhibitors.
- It is important to distinguish an immune-related adverse event from a malignant metastasis in patients receiving immune checkpoint inhibitors.
- The mechanism of rheumatologic immune-related adverse events induced by checkpoint inhibitors may provide a greater understanding of the pathogenesis of rheumatological diseases.

**References**

1. Cappelli LC, Shah AA, Bingham CO. Immune-Related Adverse Effects of Cancer Immunotherapy-Implications for Rheumatology. Rheum Dis Clin North Am 2017; 43: 65-78. [CrossRef]
2. Suarez-Almazor ME, Kim ST, Abdel-Wahab N, Diab A. Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy for Cancer. Arthritis Rheumatol 2017; 69: 687-99. [CrossRef]
3. Cappelli LC, Gutierrez AK, Bingham CO, Shah AA. Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systemic Review of the Literature. Arthritis Care Res 2016; 69: 1751-63. [CrossRef]
4. Goldstein BL, Gedmintas L, Todd DJ. Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA-4. Arthritis Rheumatol 2014; 66: 768-9. [CrossRef]
5. Dakini A, Cronin K, Srhi AG. Vasculitis associated with immune checkpoint inhibitors: a systematic review. Clin Rheumatol 2018; 37: 2579-84. [CrossRef]
6. Manusov JS, Khoja L, Pesin N, Joshua AM, Mandelcorn ED. Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma. J Immunother Cancer 2014; 2: 41. [CrossRef]
7. Minor DR, Bunker SR, Doyle J. Lymphocytic Vasculitis of the Uterus in a Patient with Melanoma Receiving Ipilimumab. J Clin Oncol 2013; 31: e356. [CrossRef]
8. Laubli H, Hench J, Stanczak M, Heinjnen I, Pachristofilou A, Frank S, Zipfelus A, et al. Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade. J Immunother Cancer 2017; 5: 1-6. [CrossRef]
9. Watanabe R, Zhang H, Berry G, Goronzzy JJ, Weyand CM. Immune checkpoint dysfunction in large and medium vessel vasculitis. Am J Physiol Heart Circ Physiol 2017; 312: H1052-9. [CrossRef]
10. Weyand CM, Berry GJ, Goronzzy JJ. The immune-inhibitory PD-1/PD-L1 pathway in inflammatory blood vessel disease. J Leukoc Biol 2018; 103: 565-55. [CrossRef]
11. Zhang H, Watanabe R, Berry GJ, Vaglio A, Yaping JL, Warrington KJ, Goronzzy JJ, et al. Immuno-inhibitory checkpoint deficiency in medium and large vessel vasculitis. Poc Natl Acad Sci USA 2017; 114: E970-E979. [CrossRef]